INTRODUCTION
Parathyroid carcinoma is an uncommon cause of primary hyperparathyroidism, accounting for 0.1% to 5% of all cases. [1] It is often under-or overdiagnosed because a lack of universal diagnostic criteria. [2] Many patients have a genetic predisposition to this tumor and have a more aggressive clinical course. [3] Clinical clues include presence of renal or bone disease; severe hypercalcemia (>14 mg/dl); very high intact parathormone (iPTH) level (more than five times the upper normal limit); the presence of lymph node and/or distant metastasis. [1] Radical surgery remains the treatment of choice; chemotherapy and radiotherapy have very limited role. [4, 5] 
CASE REPORT
A 33-year-old male presented with bilateral dull-aching flank pain for 3 years. It was not associated with fever and urinary symptoms, and was not radiating from loin to groin. There was no history of passage of stones in the urine. He had a history of left inferior parathyroidectomy 3 years ago for the management of hypercalcemia. Previous reports suggested complete tumor removal (intraoperative iPTH after 15 min of tumor removal: 7.1 pg/ml). However, the patient was lost to follow-up, until presenting to us again with recurrence after 3 years, and the biopsy report was not available. He did not have any history of jaw, pituitary or pancreatic tumors. There was no similar family history. On examination, vital signs and higher functions were normal. There was a small nodule measuring 2 × 2 cm in the left lower neck. The abdominal examination revealed no mass or organomegaly. Systemic examination was unremarkable.
Routine biochemistry including urea, creatinine, sodium, potassium and liver function tests were normal. Serum calcium was 13.7 mg/dl (albumin 4.2 g/dl), phosphorus 2.3 mg/dl and serum iPTH 1779 pg/ml, consistent with biochemical diagnosis of primary hyperparathyroidism. Computed tomography (CT) scan of the abdomen showed bilateral nephrocalcinosis [ Figure 1 ]. CT scan of the neck revealed re-growth of the tumor (4.2 cm × 2.9 cm × 1.1 cm) in the previously operated left inferior parathyroid gland region, but the lymph nodes were not enlarged [ Figure 2a ]. 99m-technetium ( 99m Tc) methoxyisobutylisonitrile scan with 20 mCi radiotracer at 3 h revealed a small fairly round-shaped area, with a mildly increased uptake of radiotracer below the lower pole of the left lobe of the thyroid [ Figure 2b ]. Further, there was no abnormal uptake elsewhere in the body. Based on the presentation and regrowth of the tumor, the possibility of parathyroid carcinoma was considered.
A radical operative procedure was planned, and the patient underwent left hemithyroidectomy with modified neck dissection. Histopathology revealed cellular atypia, pleomorphism of nuclei, prominent nucleoli, abundant eosinophilic cytoplasm [ Figure 3a ] and unequivocal capsular invasion [ Figure 3b ], further suggesting parathyroid carcinoma. The margins were free from the disease. At the time of reporting this case, the patient was planned for follow-up with regular ultrasound and serum calcium level monitoring. Genetic test for hyperparathyroidism-jaw tumor syndrome could not be performed owing to cost constraints.
DISCUSSION
Although parathyroid adenoma is a common cause of primary hyperparathyroidism, parathyroid carcinoma is rarely encountered in day-to-day practice. [1] It may occur sporadically [6] or in conjunction with familial hyperparathyroidism, hyperparathyroidism-jaw tumor syndrome or multiple endocrine neoplasia type 1 or 2A [ Table 1 ]. [7] [8] [9] [10] [11] Almost 40% of the patients present with a palpable neck mass; metabolic complications such as hypercalcemic crisis, bone or renal abnormalities are more common. [12] At the time of initial presentation, in 15%-20% of the patients, the disease is found to have spread to regional lymph nodes. Distant metastasis is also common, mostly to lungs and bones. [6] Severe hypercalcemia (>14 mg/dl), very high iPTH (five times above the normal range) and palpable neck lymph node on presentation should raise suspicion. [1] No diagnostic criteria exist, but capsular invasion, angioinvasion, nuclear atypia, fibrosis, pleomorphic cells in a trabecular growth pattern and numerous mitotic figures on histology are characteristics, and the presence of locoregional spread or distant metastasis to lungs or bones confirms the diagnosis. [12, 13] Surgical en bloc resection is the treatment of choice, as neither chemotherapy nor radiotherapy is effective. Clinical awareness is essential, as this leads to a more radical surgical approach. Almost 50% of the patients have recurrences or persistent disease, and the disease mostly recurs 2-3 years after the initial surgery, [1, 12] as was with our case. Most recurrences are locoregional and functioning, and thus regular ultrasound monitoring and serum calcium, phosphate and albumin measurements are necessary. However, nonfunctioning metastasis to bones, lungs and liver rarely occurs. [14] This disease has an overall mortality rate ranging from 51% to 78% at 10 years. Patient's age, characteristic of the histology and tumor DNA aneuploidy are predictors of survival, but tumor size or lymph node status at presentation are not. [15] The cause of death is usually from metabolic complications such as renal failure and rarely from the tumor burden. In cases of surgically inoperable parathyroid carcinoma, protocol-based chemotherapy or external beam radiation should be considered. [4, 5] For the management of hypercalcemic crisis, intravenous bisphosphonates, calcimimetics or denosumab may be used, but they do not have any effect on tumor burden. [16, 17] Novel therapy with biologic agents (e.g., gene products of parafibromin, telomerase inhibitors such as azidothymidine and immune therapy) has shown effectiveness in in vitro studies and may prove to be clinically useful in the future. [18] 
CONCLUSION
In parathyroid carcinoma, recurrence is common. Presence of characteristic cellular features, capsular invasion and angioinvasion are diagnostic. En bloc resection is the treatment of choice, as neither chemotherapy nor radiotherapy is effective.
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